Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2016 (2016), Article ID 5091951, 9 pages
http://dx.doi.org/10.1155/2016/5091951
Research Article

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan

1Medical Affairs, Global Established Pharma Business, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
2PMS Planning & Operation, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
3Clinical Informatics and Innovation, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
4Medical Writing and Document Management, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
5Clinical Statistics, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
6University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui Prefecture 910-1193, Japan

Received 10 May 2016; Accepted 5 July 2016

Academic Editor: Kazuomi Kario

Copyright © 2016 Shoko Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [1 citation]

The following is the list of published articles that have cited the current article.

  • A. L. Oei, L. E. M. Vriend, P. M. Krawczyk, M. R. Horsman, N. A. P. Franken, and J. Crezee, “Targeting therapy-resistant cancer stem cells by hyperthermia,” International Journal of Hyperthermia, vol. 33, no. 4, pp. 419–427, 2017. View at Publisher · View at Google Scholar